Cholesterol modulation as an emerging strategy for the treatment of Alzheimer's disease

Drug Discovery Today

Volumn 6, Issue 20, 2001, Pages 1049-1055

  Golde, Todd E ^a   Eckman, Christopher B ^a  

^a MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; ANTILIPEMIC AGENT; CHOLESTEROL;

ALZHEIMER DISEASE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; DRUG DEVELOPMENT; HUMAN; REVIEW;

EID: 0035888328     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(01)01965-1     Document Type: Review

References (43)

1. Biochemical detection of Aβ isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease
2. Presenilins as therapeutic targets for the treatment of Alzheimer's disease
3. Protein phosphorylation inhibits production of Alzheimer amyloid-β/A4 peptide
4. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors
5. Protein kinase C-dependent β-secretase competes with β-secretase for cleavage of amyloid-β precursor protein in the trans-Golgi network
6. Reduction of Aβ accumulation in the Tg2576 animal model of Alzheimer's disease after oral administration of the phosphatidylinositol kinase inhibitor wortmannin
7. Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neurons
8. The role of cholesterol in the biosynthesis of β-amyloid
9. Modulation of secreted β-amyloid precursor protein and amyloid β-peptide in brain by cholesterol
10. Cholesterol-dependent generation of a unique amyloid β-protein from apically missorted amyloid precursor protein in MDCK cells
11. Cholesterol-dependent generation of a seeding amyloid β-protein in cell culture
12. Cholesterol modulates α-secretase cleavage of amyloid precursor protein
13. Low cholesterol stimulates the non-amyloidogenic pathway by its effect on the α-secretase ADAM 10
14. Secretory processing of amyloid precursor protein is inhibited by increase in cellular cholesterol content (Part 3)
15. Simvastatin strongly reduces levels of Alzheimers disease β-amyloid peptides Aβ 42 and Aβ 40 in vitro and in vivo
16. Lipid binding to amyloid β-peptide aggregates: preferential binding of cholesterol as compared with phosphatidylcholine and fatty acids
17. Cholesterol-dependent formation of GM1 ganglioside-bound amyloid β-protein, an endogenous seed for Alzheimer amyloid
18. Accumulation and aggregation of amyloid-β-protein in late endosomes of Niemann-Pick type C cells
19. Functional rafts in cell membranes
20. A detergent-insoluble membrane compartment contains Aβ in vivo
21. GM1 ganglioside-bound amyloid beta-protein (Aβ): a possible form of preamyloid in Alzheimer's disease
22. Amyloid β-protein (Aβ) associated with lipid molecules: immunoreactivity distinct from that of soluble Aβ
23. The interaction between Alzheimer amyloid-β(1-40) peptide and ganglioside GM1-containing membranes
24. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families
25. Genetics of lipoprotein abnormalities associated with coronary artery disease susceptibility
26. Apolipoprotein E, a gene with complex biological interactions in the aging brain
27. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition
28. Expression of human apolipoprotein E reduces amyloid-β deposition in a mouse model of Alzheimer's disease
29. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model
30. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease
31. Fibrillogenesis in Alzheimer's disease of amyloid beta peptides and apolipoprotein E (Part 2)
32. Induction of Alzheimer-like β-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol
33. Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study
34. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease
35. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study
36. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study
37. Decreased prevalence of Alzheimer's disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors
38. Statins and the risk of dementia
39. Brain infarction and the clinical expression of Alzheimer's disease. The Nun Study
40. HMG-CoA reductase inhibitors (statins): a promising approach to stroke prevention
41. Cholesterol metabolism in the brain
42. The effects of diet and lovastatin on regression of fatty streak lesions and on hepatic and intestinal mRNA levels for the LDL receptor and HMG-CoA-reductase in F1B hamsters